term
rna
interfer
rnai
refer
cellular
process
doublestrand
rna
dsrna
sequencespecif
inhibit
express
gene
effici
process
posttranscript
gene
silenc
ptg
involv
numer
cellular
protein
besid
rna
strongli
conserv
eukaryot
presum
serv
protect
virus
genet
instabl
aris
mobil
genet
element
transposon
origin
observ
plant
correctli
describ
first
time
late
nematod
caenorhabd
elegan
achiev
andrew
fire
craig
mello
honor
nobel
prize
medicin
physiolog
measur
number
public
rnai
belong
along
proteom
dynam
field
biotechnolog
key
public
fire
mello
introduc
long
doublestrand
rna
c
elegan
observ
result
express
homolog
gene
block
sinc
basic
process
involv
determin
detail
first
step
endonucleas
dicer
process
long
dsrna
small
short
interf
rna
sirna
around
nucleotid
long
nucleotid
form
helix
nucleotid
end
unpair
figur
actual
effector
rnai
ribonucleoprotein
complex
risc
rnainduc
silenc
complex
guid
sirna
complementari
target
rna
result
target
rna
cleav
specif
site
center
duplex
nucleotid
end
sirna
strand
catalyt
compon
cleav
target
rna
slicer
activ
identifi
protein
design
argonaut
analysi
crystal
structur
show
contain
domain
resembl
rnase
h
longknown
protein
cleav
rna
compon
dnarna
duplex
cleavag
target
rna
lack
element
typic
respons
stabil
mrna
name
end
cap
polya
tail
end
cleav
mrna
rapidli
degrad
rnase
code
protein
longer
synthes
assum
load
sirna
risc
accomplish
riscload
complex
rlc
consist
drosophila
melanogast
mammalian
cell
dicer
tar
rna
bind
protein
trbp
furthermor
shown
activ
risc
strand
design
passeng
sens
strand
cleav
strand
guid
antisens
strand
remain
risc
recent
investig
reconstitut
human
rlc
demonstr
dissoci
rest
complex
load
doublestrand
rna
rna
interfer
mammalian
cell
techniqu
turn
express
specif
gene
dsrna
could
initi
appli
larg
number
eukaryot
plant
c
elegan
melanogast
could
appli
mammal
sinc
long
dsrna
trigger
unspecif
interferon
inf
respons
mammalian
cell
dsrna
interpret
cell
pathogen
protein
kinas
r
activ
termin
protein
synthesi
affect
cell
furthermor
enzym
induc
produc
oligoadenyl
therebi
caus
rnase
ldepend
unspecif
degrad
singlestrand
rna
sinc
inf
respons
trigger
dsrna
longer
nucleotid
realiz
rnai
induc
rna
approxim
nucleotid
provid
solut
problem
groundbreak
work
chemic
synthes
sirna
trigger
rnai
mammalian
cell
tuschl
cowork
open
way
use
rnai
experi
mammalian
cell
creat
new
opportun
research
also
therapeut
treatment
presynthes
sirna
phosphoryl
end
kinas
enter
cell
follow
rnai
pathway
describ
figur
b
rnai
expand
repertoir
alreadi
well
known
oligonucleotidebas
strategi
ptg
antisens
oligonucleotid
employ
last
year
inhibit
express
gene
mrna
level
antisens
rnai
strategi
mani
thing
common
necess
identifi
suitabl
bind
sequenc
target
rna
stabil
oligonucleotid
chemic
modif
transport
neg
charg
polym
across
cell
membran
experi
antisens
field
allow
rapid
progress
made
new
rnai
strategi
howev
import
differ
two
technolog
antisens
oligonucleotid
singlestrand
modifi
dna
molecul
primarili
induc
cleavag
target
rna
cell
nucleu
activ
rnase
h
contrast
rnai
trigger
doublestrand
rna
function
primarili
cytoplasm
import
compon
risc
local
p
bodi
result
central
step
rnai
appear
take
place
discret
structur
cytoplasm
case
rnai
endogen
cellular
pathway
follow
could
explain
high
effici
sirna
abl
inhibit
express
target
gene
time
effici
tradit
antisens
oligonucleotid
target
molecul
particularli
import
region
could
determin
normal
nucleotid
long
antisens
oligonucleotid
seed
region
posit
antisens
strand
figur
great
import
sirna
sinc
presum
interact
target
rna
begin
effect
sirna
transient
degrad
target
rna
usual
begin
immedi
sirna
enter
cell
howev
decreas
amount
protein
depend
halflif
target
protein
normal
pronounc
inhibitori
effect
observ
cell
cultur
within
h
transfect
sirna
howev
protein
slow
rate
turnov
stabl
much
longer
also
one
must
keep
mind
case
target
gene
complet
shut
rnai
refer
knockdown
technolog
oppos
knockout
case
transgen
anim
creat
homolog
recombin
inhibit
express
target
gene
usual
last
five
seven
day
vitro
vivo
interestingli
sirna
work
differ
length
time
differ
speci
sirna
apolipoprotein
b
activ
mice
day
nine
day
back
initi
start
level
wherea
knockdown
nonhuman
primat
still
effect
day
durat
action
sirna
presum
depend
numer
factor
target
organ
target
gene
speci
intracellularli
express
short
hairpin
rna
shrna
use
instead
chemic
synthes
sirna
extend
gene
silenc
see
figur
b
section
rnai
primarili
process
ptg
gene
express
inhibit
select
blockad
mrna
also
report
rnai
alter
chromatin
structur
nucleu
therebi
influenc
transcript
observ
particular
yeast
plant
fruit
fli
import
rnai
transcript
deoxythymidin
often
use
overhang
chemic
synthes
sirna
posit
complementari
target
rna
cleav
indic
arrow
seed
region
interact
target
rna
begin
indic
b
simplifi
model
rnai
mechan
mammalian
cell
uptak
chemic
synthes
sirna
cell
load
onto
risc
rlc
cours
sens
strand
remov
antisens
strand
guid
risc
complementari
target
rna
cleav
protein
longer
term
inhibit
gene
express
accomplish
shrna
express
intracellularli
instead
exogen
applic
sirna
figur
adapt
ref
gene
silenc
mammal
contrast
yet
clearli
demonstr
besid
previous
describ
sirna
employ
research
tool
potenti
therapeut
artifici
regul
gene
express
import
endogen
short
rna
code
protein
becom
increas
clear
role
approxim
nucleotid
long
microrna
mirna
posttranscript
regul
gene
investig
intens
last
year
version
mirbas
data
base
http
micrornasangeracuk
april
mirna
list
anim
plant
virus
human
alon
mirna
predict
nucleu
mirna
precursor
primirna
form
special
mirna
gene
intron
proteincod
polymeras
ii
transcript
process
rnase
iii
drosha
approxim
nucleotid
long
premirna
transport
nucleu
cleav
dicer
becom
function
mirna
figur
similar
sirna
also
form
ribonucleoprotein
complex
argonaut
protein
bind
target
rna
howev
mirna
preferenti
recogn
target
sequenc
region
mrna
bind
often
take
place
incomplet
homolog
although
perfect
base
pair
previous
mention
seed
region
posit
mirna
form
core
interact
depend
degre
homolog
mirna
mrna
result
irrevers
cleavag
target
molecul
mere
repress
translat
precis
mechan
mirnadepend
posttransl
repress
gene
express
current
subject
intens
research
accord
two
import
model
either
translat
block
mrna
destabil
inhibit
translat
could
take
place
level
initi
process
assum
complex
interact
cap
structur
end
bind
mrna
therebi
prevent
bind
initi
factor
result
initi
complex
form
altern
translat
could
slow
initi
ribosom
could
dissoci
prematur
accord
altern
model
mrna
deadenyl
mirna
make
degrad
possibl
cap
remov
would
enabl
degrad
direct
exonucleas
possibl
mechan
mirna
could
work
assum
mirna
control
activ
proteincod
gene
mammal
sinc
everi
mirna
regul
numer
mrna
turn
mrna
influenc
numer
mirna
result
extrem
complex
regulatori
network
hardli
surpris
mirna
involv
cellular
process
investig
play
import
role
numer
diseas
cancer
viral
infect
genet
diseas
inform
concern
activ
function
mirna
reader
refer
recent
review
articl
class
short
regulatori
rna
associ
piwi
protein
thu
refer
pirna
rna
around
nucleotid
length
slightli
longer
typic
sirna
mirna
presum
process
singlestrand
precursor
found
princip
germ
cell
besid
import
control
mobil
genet
element
function
spermatogenesi
also
suspect
recent
endogen
sirna
esirna
found
comprehens
sequenc
short
rna
mammalian
cell
mous
oocyt
previous
assum
rnadepend
rna
polymeras
activ
requir
product
esirna
found
mammal
shown
doublestrand
rna
long
hairpin
structur
complementari
sequenc
serv
start
point
product
esirna
esirna
deriv
retrotransposon
appar
function
inhibitor
addit
esirna
figur
mirna
pathway
mammalian
cell
rna
transcrib
nucleu
form
precursor
primirna
process
rnase
iii
drosha
premirna
process
drosha
complex
protein
premirna
export
nucleu
cytoplasm
cleav
dicer
complex
trbp
form
function
mirna
turn
combin
argonaut
protein
ago
form
mirnaribonucleoprotein
mirnp
complex
mirna
either
caus
endonucleolyt
cleavag
target
mrna
block
translat
case
partial
complementar
figur
adapt
ref
pseudogen
found
could
signific
regul
proteincod
transcript
first
import
step
success
applic
rnai
design
effici
sirna
origin
assumpt
necessari
search
suitabl
target
sequenc
target
rna
prove
optimist
practic
effici
differ
sirna
target
rna
vari
drastic
appar
factor
intrins
sirna
characterist
target
rna
play
role
silenc
probabl
identifi
effici
sirna
significantli
increas
discov
strand
sirna
mirna
equal
like
incorpor
risc
instead
strand
lower
thermodynam
stabil
name
higher
content
end
prefer
thereaft
molecular
basi
strand
asymmetri
could
determin
melanogast
risc
load
heterodim
dsrnabind
protein
bind
thermodynam
stabl
end
doublestrand
rna
thu
determin
strand
associ
risc
guid
strand
detail
studi
sirna
two
differ
rna
target
besid
rel
stabil
two
end
addit
criteria
prefer
special
base
certain
posit
identifi
common
among
function
sirna
experi
howev
signific
paramet
determin
independ
one
anoth
also
take
account
synergist
influenc
multipl
link
paramet
artifici
neuron
network
train
dataset
sirna
differ
mrna
biopredsialgorithm
extens
survey
activ
publish
sirna
shown
howev
number
activ
sirna
correspond
propos
criteria
numer
care
design
sirna
inact
recent
even
hypothesi
rel
stabil
two
end
influenc
effici
call
question
neither
experiment
investig
set
differ
sirna
comprehens
analysi
publish
sirna
sirna
post
databank
could
correl
termin
stabil
sirna
silenc
activ
found
characterist
sirna
also
possibl
play
role
exampl
shown
sirna
whose
antisens
strand
form
stabl
helic
end
show
low
level
activ
author
advis
therefor
design
sirna
antisens
strand
unstructur
possibl
besid
sirna
target
rna
could
also
play
import
role
silenc
could
help
explain
express
target
easili
inhibit
knockdown
other
difficult
studi
sever
thousand
sirna
conceiv
differ
gene
accord
biopredsi
algorithm
investig
kinas
gene
easi
silenc
defin
two
two
test
sirna
work
gene
could
downregul
differ
sirna
studi
antisens
oligonucleotid
alreadi
shown
access
bind
region
target
rna
oligonucleotid
great
import
effici
silenc
correspond
access
antisens
oligonucleotid
sirna
demonstr
comprehens
analysi
access
target
rna
predict
iter
bioinformat
approach
experiment
rnase
h
map
result
show
sirna
predict
highli
access
area
effici
whose
target
sequenc
inaccess
rel
thermodynam
stabil
two
end
sirna
prove
contrast
suitabl
criterion
predict
effici
sirna
analyz
influenc
silenc
thermodynam
design
sirna
access
target
rna
close
help
artifici
target
structur
abl
confirm
report
assay
strand
asymmetri
name
target
sequenc
natur
orient
led
stronger
silenc
way
around
hand
clear
correl
local
free
energi
sirna
bind
region
silenc
therefor
propos
twostep
model
describ
inhibitori
effici
sirna
figur
initi
thermodynam
characterist
sirna
rel
stabil
two
end
determin
asymmetr
incorpor
two
strand
risc
second
step
access
bind
region
twostep
model
explain
effici
sirna
sens
strand
antisens
strand
depend
rel
stabil
two
end
sirna
one
two
strand
preferenti
assembl
risc
retent
strand
complementari
target
rna
achiev
select
suitabl
sequenc
antisens
strand
assembl
risc
howev
unsuit
silenc
complementari
sequenc
target
rna
inaccess
local
structur
target
region
thu
also
influenc
silenc
significantli
figur
adapt
ref
permiss
elsevi
sirna
target
rna
affect
strength
silenc
model
confirm
analysi
around
sirna
shrna
differ
human
gene
accord
studi
access
target
rna
sirna
greater
import
duplex
asymmetri
effici
knockdown
report
shown
access
end
target
rna
particularli
import
alreadi
mention
section
interact
sirna
mirna
target
rna
begin
seed
region
algorithm
design
sirna
sfold
web
server
take
account
thermodynam
characterist
duplex
also
predict
secondari
structur
target
rna
must
emphas
none
model
propos
far
guarante
success
predict
activ
sirna
must
therefor
factor
still
need
identifi
particular
synergist
effect
influenc
effici
rnai
experi
convent
sirna
consist
duplex
two
nucleotid
long
overhang
end
howev
report
longer
sirna
effici
experi
sirna
variou
length
mer
effici
time
higher
convent
mer
studi
shrna
proven
especi
potent
long
duplex
initi
process
mer
dicer
thu
presum
effici
assembl
risc
rlc
problem
design
individu
sirna
bypass
use
enzymat
synthes
sirna
pool
first
long
dsrna
gener
process
bacteri
synthes
rnase
iii
recombin
dicer
endoribonucleaseprepar
sirna
mix
sirna
harbor
risk
increas
offtarget
effect
see
section
hand
individu
sirna
present
low
concentr
undesir
side
effect
appar
dilut
method
inexpens
comprehens
librari
complet
human
mous
genom
manufactur
although
unmodifi
sirna
use
cell
cultur
advantag
build
modifi
nucleotid
sirna
specif
inhibit
express
gene
primari
reason
chemic
modif
sirna
increas
resist
nucleolyt
degrad
fact
although
sirna
unexpectedli
long
life
usual
necessari
stabil
use
modifi
nucleotid
vivo
applic
modif
often
lengthen
halflif
sirna
plasma
improv
pharmacokinet
characterist
furthermor
new
function
introduc
fluoresc
marker
lipophil
group
exampl
improv
cellular
uptak
rapid
success
incorpor
chemic
modifi
compon
attribut
experi
gain
field
antisens
technolog
multitud
modifi
nucleotid
employ
past
year
sirna
sever
select
exampl
explain
detail
explain
extens
comprehens
review
articl
incorpor
unnatur
nucleotid
sirna
present
particular
challeng
sinc
modif
must
affect
silenc
activ
sirna
context
import
rememb
two
strand
sirna
differ
function
guid
strand
assembl
risc
lead
complex
target
rna
passeng
strand
discard
load
risc
passeng
strand
therefor
like
toler
modif
guid
strand
also
modifi
nucleotid
built
suitabl
posit
particular
import
hydroxi
group
end
guid
strand
must
phosphoryl
entri
sirna
rnai
pathway
correspondingli
sirna
whose
end
blockedfor
exampl
amino
linkerlos
inhibitori
activ
compar
simpl
contrast
incorpor
function
group
end
passeng
strand
way
possibl
follow
local
sirna
fluorophor
end
passeng
strand
without
grave
influenc
silenc
activ
furthermor
cellular
penetr
sirna
improv
lipophil
compon
acid
cholesterol
see
also
section
common
modif
stabil
antisens
oligonucleotid
phosphorothio
dna
unlink
oxygen
atom
substitut
sulfur
atom
phosphorothio
stabl
respect
nucleas
compar
simpl
manufactur
rna
variant
phosphorothio
figur
therefor
also
built
sirna
modif
fundament
toler
rnai
machineri
howev
toxic
side
effect
observ
phosphorothio
content
high
nucleotid
also
use
whose
ribos
modifi
exampl
rna
chemi
nucleotid
figur
fluoro
substitu
small
serious
influenc
function
sirna
significantli
larger
methyl
group
contrast
inhibit
rnai
function
entir
sirna
consist
nucleotid
therefor
modif
type
sought
increas
stabil
sirna
without
reduc
silenc
activ
bluntend
sirna
prove
suitabl
rna
unit
nucleotid
altern
strand
modifi
nucleotid
opposit
unmodifi
one
modifi
sirna
inject
mice
compon
lipoplex
see
section
sirna
taken
vascular
endotheli
cell
reduc
level
target
mrna
target
protein
modif
commonli
use
past
year
lock
nucleic
acid
lna
figur
lna
numer
desir
characterist
high
nucleas
stabil
high
affin
target
structur
incorpor
rna
duplex
howev
caus
seriou
structur
chang
complet
modif
sirna
lna
therefor
imposs
lna
monom
built
sirna
without
loss
silenc
abil
systemat
studi
posit
antisens
strand
identifi
toler
substitut
rna
nucleotid
lna
compon
without
loss
activ
incorpor
lna
sirna
increas
nucleas
stabil
also
reduc
offtarget
effect
sirna
see
section
inactiv
sens
strand
increas
effici
sirna
improv
load
risc
correspond
lnamodifi
sirna
show
favor
characterist
system
use
vivo
compar
unmodifi
sirna
use
method
inactiv
strand
sirna
incorpor
lna
analyz
detail
mechan
rnaiinduc
inhibit
coxsacki
viru
cardiotrop
virus
belong
famili
picornavirida
possess
singl
positivestrand
genom
replic
neg
strand
copi
intermedi
select
inactiv
one
two
strand
lna
show
sirna
genom
posit
strand
possess
antivir
activ
studi
triplestrand
sirna
construct
employ
antisens
strand
hybrid
two
shorter
nucleotid
long
complementari
strand
socal
small
intern
segment
interf
rna
sisirna
modifi
variou
posit
lna
high
serum
stabil
silenc
activ
fact
variou
modif
differ
posit
sirna
could
built
sirna
without
drastic
loss
activ
suggest
possibl
combin
variou
type
rna
analogu
way
oh
group
sirna
could
substitut
success
pyrimidin
replac
nucleotid
purin
sens
strand
deoxyribonucleotid
use
purin
antisens
strand
furthermor
end
protect
invert
abas
sugar
phosphorothio
bond
complet
modifi
sirna
halflif
human
serum
sever
day
oppos
sever
minut
unmodifi
form
significantli
effici
start
sirna
vectorbas
vivo
model
hepat
b
viru
hbv
infect
great
disadvantag
chemic
synthes
sirna
activ
transient
last
sever
day
sirna
degrad
time
dilut
cell
divis
therefor
major
advanc
sever
research
group
simultan
develop
express
system
sirna
continu
gener
cell
common
system
sirna
convert
dna
sequenc
code
sens
strand
loop
antisens
strand
dna
templat
transcrib
vector
control
polymeras
iii
promot
promot
optim
gener
larg
amount
precis
defin
rna
commonli
use
promot
compon
spliceosom
well
promot
rna
compon
rnase
p
transcript
selfcomplementari
rna
creat
refer
shrna
shrna
process
intracellularli
dicer
sirna
mediat
silenc
shrna
express
system
led
creation
new
applic
rnai
usual
vectorexpress
shrna
work
significantli
longer
chemic
synthes
sirna
plasmid
equip
resist
gene
use
select
transfect
cell
line
target
gene
downregul
sever
month
addit
transgen
anim
gener
gene
interest
perman
inhibit
use
shrna
express
vector
exampl
shrna
express
cassett
incorpor
embryon
mous
stem
cell
electropor
lentivir
transfer
see
section
problem
method
integr
transgen
random
silenc
effici
vari
consider
depend
integr
site
furthermor
import
cellular
gene
destroy
reason
locu
sought
guarante
strong
predict
shrna
express
rosa
locu
fulfil
requir
use
integr
transgen
homolog
recombinasemedi
cassett
exchang
rmce
knockdown
singl
copi
shrnaexpress
cassett
analyz
organ
advantag
procedur
rel
convent
knockout
techniqu
immens
save
time
shrnaexpress
anim
avail
investig
around
three
four
month
knockout
anim
backcross
take
sever
year
often
necessari
gene
delet
chromosom
genet
defin
background
surprisingli
recent
observ
phenotyp
differ
knockout
shrnaexpress
anim
studi
function
vanilloid
receptor
play
import
role
pain
percept
investig
detail
reaction
shrnaexpress
anim
accord
publish
data
anim
test
capsaicininduc
hypothermia
coliti
reaction
heat
stimulu
show
pronounc
differ
percept
neuropath
pain
knockout
impact
percept
neuropath
pain
mechan
hypersensit
allodynia
shrnaexpress
anim
significantli
reduc
comparison
wildtyp
anim
find
agre
result
small
molecul
receptor
antagonist
caus
differ
behavior
knockout
shrnaexpress
anim
yet
fulli
understood
howev
complet
knockout
partial
knockdown
appear
lead
differ
compens
mechan
one
keep
mind
small
molecul
pharmacolog
substanc
also
partial
inhibit
target
partial
knockdown
rnai
experi
may
better
reflect
outcom
medicin
therapi
substanc
direct
target
advantag
rnai
technolog
broad
applic
classic
knockout
homolog
recombin
routin
done
mice
shrna
vector
technolog
allow
gene
turn
speci
rat
develop
idea
creation
diseaseresist
domest
anim
help
rnai
goat
foetus
bovin
blastocyst
rnai
shut
prion
protein
prp
aggreg
transmiss
spongiform
encephalopathi
tse
way
possibl
gener
domest
anim
resist
bse
relat
diseas
cattl
could
made
resist
footandmouth
diseas
use
similar
method
creation
transgen
domest
anim
howev
result
technolog
challeng
also
ethic
social
implic
must
neglect
shrna
system
describ
far
express
control
polymeras
iii
promot
modern
system
also
employ
polymeras
ii
promot
result
transcript
cap
end
polya
tail
end
compat
rnai
machineri
nevertheless
use
polymeras
ii
promot
express
mirna
simul
altern
usual
compon
longer
premrna
transcrib
control
polymeras
ii
promot
natur
occur
mirna
replac
artifici
shrna
sequenc
context
mirna
rna
polymeras
ii
first
gener
long
primari
transcript
drosha
cut
premirna
export
cytoplasm
dicer
process
sirna
assembl
risc
compar
studi
convent
mirnatyp
shrna
hiv
shown
latter
effici
besid
high
effici
mirnatyp
shrna
advantag
rel
classic
shrna
one
thing
allow
simultan
express
proteincod
sequenc
upstream
mirna
segment
way
report
gfp
relev
function
protein
express
shrna
time
secondli
polycistron
express
becom
possibl
one
micrornatyp
shrna
express
time
singl
transcript
manner
either
sever
gene
silenc
target
gene
effici
inhibit
sever
shrna
third
advantag
option
use
celltypespecif
promot
polymeras
iii
promot
mediat
strong
ubiquit
express
larg
number
differ
polymeras
ii
promot
activ
certain
condit
specif
cell
type
exampl
mirnatyp
shrna
transcript
factor
wilm
tumor
express
control
proxim
promot
murin
gene
specif
inhibit
express
target
gene
nurs
cell
testi
vector
system
also
provid
opportun
regul
rnai
pharmacolog
substanc
system
may
differenti
revers
irrevers
type
revers
system
express
shrna
turn
addit
induc
induc
taken
away
transcript
shrna
ceas
target
gene
sirna
express
irrevers
system
shrna
express
induc
turn
form
regul
wide
employ
gene
essenti
embryon
develop
investig
adult
organ
common
revers
shrna
express
system
base
tetracyclin
tet
control
transcript
tet
control
promot
usual
modifi
addit
tet
operon
repressor
protein
bind
addit
inducersuch
tetracyclin
commonli
use
structur
analogu
doxycyclin
dox
result
structur
chang
tet
repressor
induc
releas
tet
operon
open
way
transcript
shrna
tet
system
function
vitro
well
vivo
exampl
shrna
pololik
kinas
doxdepend
express
studi
import
target
gene
prolifer
cancer
cell
shown
inocul
cell
immunodefici
nude
mice
rnaimedi
silenc
could
modul
doxdepend
manner
vivo
studi
transgen
anim
gener
accord
previous
describ
rmce
procedur
shrna
express
could
revers
induc
dox
way
target
gene
code
insulin
receptor
could
downregul
chosen
period
time
tet
system
combin
numer
advantag
low
background
activ
absenc
induc
strongli
induc
quickli
revers
remov
induc
induc
tetracyclin
doxycyclin
nontox
wellcharacter
pharmacolog
substanc
besid
describ
system
numer
variant
tet
control
revers
regul
system
explain
recent
review
articl
crelox
system
wide
use
mani
year
convent
knockout
also
employ
irrevers
method
condit
rnai
system
transcript
function
shrna
destroy
insert
addit
dna
segment
express
cassett
exampl
neomycin
neo
resist
gene
flank
two
loxp
site
integr
shrnacod
region
cre
recombinas
remov
interrupt
sequenc
express
cell
induc
synthesi
shrna
altern
stuffer
sequenc
also
insert
promot
region
crelox
system
allow
tempor
control
rnai
suppress
exampl
induct
embryon
develop
well
tissuespecif
silenc
cre
recombinas
express
certain
cell
type
small
molecular
pharmacolog
substanc
typic
bind
protein
inhibit
catalyt
core
block
membranebound
receptor
usual
bind
target
molecul
spatial
interact
often
result
undesir
side
effect
substanc
also
bind
structur
similar
protein
sinc
rnai
applic
base
watsoncrick
base
pair
oligonucleotid
rna
hope
undesir
side
effect
play
role
target
sequenc
appear
genom
use
practic
singl
mismatch
lead
complet
loss
silenc
extens
microarray
analys
global
profil
gene
express
creat
show
howev
sirna
complet
specif
initi
studi
suggest
socal
offtarget
effect
sirna
dosedepend
avoid
use
lower
concentr
sirna
studi
show
unspecif
effect
similar
dose
respons
intend
knockdown
target
gene
ident
eleven
nucleotid
antisens
strand
sirna
mrna
result
downregul
mrna
intend
target
offtarget
effect
effect
phenotyp
exampl
viabil
cell
recent
investig
shown
overal
ident
mrna
sirna
rather
perfect
correspond
part
seed
region
posit
antisens
strand
sirna
determin
whether
gene
express
influenc
figur
systemat
studi
frequenc
possibl
hexam
transcriptom
investig
shown
hexam
rare
other
consider
common
becam
clear
microarray
analysi
sirna
common
seed
region
trigger
stronger
offtarget
effect
complementari
sequenc
mean
offtarget
effect
reduc
clever
design
sirna
furthermor
specif
sirna
reduc
incorpor
modifi
nucleotid
compar
easi
complet
inactiv
sens
strand
modif
danger
offtarget
regul
reduc
minimum
chang
antisens
strand
hand
challeng
sinc
inhibitori
effect
express
target
gene
must
influenc
singl
substitut
ribos
second
nucleotid
shown
enough
significantli
reduc
offtarget
effect
maintain
silenc
activ
figur
besid
regul
partial
homolog
mrna
sirna
surprisingli
also
trigger
interferon
inf
respons
although
origin
assum
respons
induc
doublestrand
rna
molecul
greater
nucleotid
length
complet
analysi
infstimul
gene
reveal
howev
sirna
also
activ
interferon
system
presum
mediat
protein
kinas
r
effect
specif
sirna
also
observ
vectorexpress
shrna
presum
tolllik
receptor
tlr
helicas
addit
protein
kinas
r
also
play
import
role
recognit
sirna
immun
system
three
member
tlr
famili
recogn
rna
trigger
immun
respons
complex
signal
pathway
figur
could
shown
plasmacytoid
dendrit
cell
sirna
induc
infa
via
activ
effect
sirna
endosom
tlr
depend
sequenc
sirna
result
motif
could
identifi
led
strong
induct
immun
respons
mean
immunostimul
circumv
avoid
use
motiv
sirna
special
applic
treatment
viral
infect
cancer
strongli
immunomodulatori
sirna
two
function
knockdown
target
gene
induct
interferon
could
use
deliber
recent
public
report
unspecif
effect
sirna
also
mediat
investig
antiangiogenet
effect
sirna
use
exampl
treatment
agerel
macular
degener
see
section
show
anim
model
unspecif
sirna
without
homolog
sequenc
mammalian
genom
effici
sirna
vascular
endotheli
growth
factor
vegf
receptor
effect
depend
sequencespecif
silenc
target
offtarget
rnai
infab
activ
instead
choroid
neovascular
block
adaptor
trif
local
variou
cell
type
cell
surfac
well
induct
infg
undesir
side
effect
come
crossreact
endogen
mirna
pathway
explain
introduct
sirna
mirna
function
similar
mechan
reason
hardli
surpris
sirna
act
mirna
mean
sirna
interact
mrna
partial
homolog
inhibit
translat
without
trigger
degrad
furthermor
express
shrna
block
endogen
mirna
pathway
pronounc
liver
toxic
observ
high
dose
viral
vector
carri
shrna
express
cassett
inject
mice
shrna
test
caus
liver
damag
case
fatal
presum
cellular
mirna
pathway
disturb
among
thing
oversatur
respons
transport
mirna
precursor
nucleu
cytoplasm
side
effect
observ
lower
concentr
vector
contrast
protect
hbv
achiev
anim
model
year
respons
work
recent
publish
studi
investig
whether
chemic
synthes
sirna
influenc
cellular
mirna
liposom
deliveri
sirna
result
express
hepatocytespecif
gene
inhibit
around
level
function
sever
investig
mirna
influenc
sirna
treatment
conclus
clear
rnai
applic
never
complet
specif
suitabl
design
sirna
well
use
modifi
nucleotid
howev
unspecif
effect
minim
addit
dose
sirna
shrna
low
possibl
reliabl
result
function
analys
increas
verifi
phenotyp
multipl
independ
sirna
therapeut
applic
must
rememb
small
molecular
substanc
usual
also
numer
toxic
side
effect
reason
safeti
standard
appli
preclin
develop
rnai
applic
substanc
oligonucleotid
multipli
neg
charg
macromolecul
cross
hydrophob
cell
membran
difficulti
deliveri
sirna
cell
present
one
greatest
challeng
develop
rnai
applic
cellcultur
applic
transfect
reagent
commonli
use
often
toxic
side
effect
anim
human
previou
work
antisens
field
establish
certain
amount
oligonucleotid
spontan
taken
cell
vivo
thu
sirna
also
work
without
carrier
local
appli
intranas
deliveri
intrathec
inject
rememb
case
local
applic
creat
high
concentr
sirna
spatial
restrict
area
addit
measur
requir
effici
system
deliveri
basic
approach
divid
nonvir
deliveri
chemic
synthes
sirna
viral
deliveri
shrna
express
cassett
prefer
method
depend
applic
temporari
diseas
acut
infect
shortact
sirna
suffici
chronic
diseas
hiv
infect
metabol
diseas
vectorbas
method
presum
advantag
avoid
repeat
dose
first
vivo
applic
rnai
free
sirna
appli
hydrodynam
inject
tail
vein
involv
inject
rel
larg
volum
sirna
solut
short
time
high
pressur
way
sirna
preferenti
taken
liver
proof
principl
demonstr
practic
knockdown
target
gene
target
organ
method
howev
harsh
viabl
human
reason
intens
work
develop
biocompat
procedur
deliveri
sirna
go
mani
year
vivo
system
applic
sirna
requir
overcom
numer
barrier
unfold
activ
free
oligonucleotid
rapidli
filter
blood
kidney
subsequ
excret
addit
unmodifi
sirna
rapidli
degrad
nucleas
see
section
foreign
macromolecul
phagocyt
reticuloendotheli
system
deposit
liver
spleen
halflif
sirna
bloodstream
extend
hydrophob
polym
polyethylen
glycol
peg
sirna
must
overcom
capillari
endothelium
diffus
extracellular
matrix
target
tissu
uptak
cell
normal
occur
endocytosi
import
step
releas
sirna
endosom
cytoplasm
manifest
activ
numer
method
aid
process
import
discuss
mani
substanc
pack
liposom
improv
pharmacokinet
characterist
liposom
form
phospholipid
bilay
surround
aqueou
compart
polar
substanc
store
mediat
uptak
substanc
cell
form
vesicular
transport
exampl
endosom
cation
lipid
particularli
well
suit
deliveri
neg
charg
nucleic
acid
commerci
avail
transfect
reagent
form
lipoplex
oligonucleotid
lipoplex
sirna
contain
inner
compart
howev
numer
new
lesstox
formul
develop
vivo
applic
usual
lipoplex
liposom
surround
peg
figur
b
achiev
longer
circul
blood
stream
reduc
toxic
addit
fusogen
lipid
ad
improv
releas
sirna
endosom
free
sirna
rapidli
excret
kidney
intraven
inject
sirna
label
fluoresc
dye
administ
sirna
lipoplex
could
detect
mani
organ
sirna
remain
unfortun
primarili
endotheli
cell
blood
vessel
therefor
bare
penetr
tissu
liposom
deliveri
complet
modifi
sirna
hbv
describ
section
increas
effici
durat
action
mous
model
sirna
encapsul
stabl
nucleic
acidlipid
particl
snalp
consist
cation
fusogen
lipid
also
pegyl
figur
b
snalp
subsequ
use
test
sirna
apolipoprotein
b
primat
level
mrna
liver
reduc
singl
inject
result
protein
serum
cholesterol
level
lowdens
lipoprotein
ldl
reduc
show
liposomemedi
sirna
deliveri
could
success
test
clinic
relev
context
knockdown
apolipoprotein
b
demonstr
two
aspect
first
partial
reduct
target
protein
suffici
reach
relev
therapeut
benefit
name
reduct
ldl
normal
level
use
rnai
tumor
viral
infect
howev
greatest
possibl
knockdown
target
gene
must
reach
prevent
relaps
diseas
secondli
figur
nonvir
deliveri
sirna
lipoplex
cation
lipid
gray
form
complex
neg
charg
sirna
red
peg
yellow
frequent
attach
improv
pharmacokinet
characterist
b
liposom
cation
lipid
enclos
sirna
c
sirna
coupl
cholesterol
increas
lipophil
specif
deliveri
coupl
sirna
antigenbind
fragment
antibodi
posit
charg
protamin
e
direct
coupl
sirna
aptam
tumorcellspecif
deliveri
f
neuron
deliveri
peptid
rabi
viru
glycoprotein
rvg
arginin
nonam
carboxi
terminu
bind
sirna
g
receptormedi
deliveri
coupl
ligand
f
folat
dna
oligonucleotid
blue
hybrid
sirna
sens
strand
green
antisens
strand
red
detail
describ
text
advantag
rnai
technolog
lie
fact
chosen
gene
inhibit
socal
drugabl
target
tradit
smallmolecul
substanc
direct
besid
lipidbas
system
variou
polym
employ
deliveri
sirna
one
intens
investig
polym
deliveri
nucleic
acid
polyethyleneimin
pei
linear
branch
pei
polym
strongli
posit
charg
therefor
form
complex
sirna
electrostat
interact
cell
surfac
complex
taken
endocytosi
pei
improv
releas
sirna
destroy
endosom
peisirna
complex
employ
success
limit
influenza
infect
mice
exampl
nanoparticl
complet
differ
substanc
also
develop
exampl
medarova
et
al
use
nanoparticl
system
applic
allow
deliveri
proof
sirna
uptak
time
sampl
consist
magnet
nanoparticl
label
dye
absorb
nearinfrar
region
accumul
tumor
could
observ
magnet
reson
imag
mri
nearinfrar
vivo
optic
imag
nirf
nanoparticl
equip
myristoylcoupl
polyarginin
peptid
transloc
across
membran
altern
system
carbon
fiber
nanotub
use
facilit
entri
sirna
cell
primari
cell
otherwis
difficult
transfect
liposom
system
altern
strategi
coupl
lipophil
molecul
directli
sirna
seri
test
group
cholesterol
acid
coupl
end
sens
strand
prove
best
suit
ensur
effici
uptak
cell
knockdown
target
gene
result
cholersterolcoupl
sirna
figur
c
inject
tail
vein
mice
cellular
uptak
silenc
target
protein
apolipoprotein
b
could
shown
liver
jejunum
section
small
intestin
addit
lipophil
group
cellpenetr
peptid
cpp
improv
cellular
uptak
oligonucleotid
interestingli
phosphorothio
oligonucleotid
coval
attach
sirna
improv
uptak
caveolinmedi
mechan
result
express
lamin
primari
huvec
endotheli
cell
inhibit
develop
system
allow
specif
deliveri
sirna
target
cell
repres
great
advanc
approach
allow
appli
dose
smaller
possibl
side
effect
tissu
avoid
eleg
possibl
consist
coupl
sirna
antibodi
recogn
protein
surfac
special
cell
groundbreak
studi
antigenbind
fragment
antibodi
hiv
glycoprotein
fuse
protamin
use
figur
posit
charg
protein
assembl
approxim
six
neg
charg
sirna
noncoval
manner
construct
possibl
inhibit
hiv
infect
primari
cell
difficult
transfect
lipidbas
strategi
author
succeed
vivo
antibodi
strategi
deliv
sirna
tumor
cell
present
ligand
protein
antibodi
cell
surfac
avoid
need
combin
two
class
molecul
protein
nucleic
acid
sirna
coupl
aptamersligandbind
vitro
select
nucleic
acid
first
effort
streptavadin
bridg
use
bind
sirna
lamin
aptam
prostatespecif
membran
antigen
psma
membran
receptor
express
prostat
cancer
cell
vascular
endothelia
tumor
conjug
made
effici
silenc
possibl
rel
complex
biotinstreptavadin
bridg
reason
sirna
coupl
directli
differ
aptam
psma
studi
figur
e
cell
sirna
remov
aptam
dicer
anim
model
possibl
inhibit
growth
tumor
human
prostat
carcinoma
cell
aptamercoupl
sirna
treatment
neurolog
diseas
complic
need
pass
bloodbrain
barrier
often
prevent
entri
drug
bloodstream
brain
overcom
barrier
amino
acid
long
peptid
rabi
viru
glycoprotein
coupl
arginin
nonam
sirna
figur
f
peptid
bound
acetylcholin
receptor
express
neuron
cell
conjug
specif
penetr
neuron
vivo
intraven
inject
sirna
peptid
succeed
get
brain
cell
protect
mice
infect
japanes
enceph
viru
possibl
celltypespecif
deliveri
coupl
receptor
ligand
folat
dna
oligonucleotid
figur
g
dna
oligonucleotid
hybrid
extend
end
antisens
strand
sirna
ligand
mediat
uptak
cell
construct
consist
two
rna
molecul
dna
oligonucleotid
presum
dicer
rnase
h
produc
matur
sirna
detail
concern
nonvir
deliveri
sirna
describ
recent
publish
review
virus
belong
danger
pathogen
human
therapi
often
inadequ
avail
last
year
howev
concept
pursu
introduc
therapeut
use
gene
patient
help
viral
vector
process
virus
usual
chang
essenti
compon
replic
miss
produc
progeni
virus
therefor
harm
patient
other
figur
although
worldwid
gene
transfer
almost
clinic
trial
real
breakthrough
gene
therapi
yet
accomplish
high
hope
place
combin
new
effici
rnai
technolog
experi
gene
angewandt
chemi
therapi
involv
get
shrna
express
cassett
cell
mean
viral
vector
form
gene
transfer
usual
significantli
effici
nonvir
deliveri
sirna
three
type
vector
primarili
use
retrovir
vector
adenovir
vector
well
vector
base
adenoassoci
viru
aav
import
advantag
disadvantag
three
vector
type
summar
tabl
past
experi
shown
imposs
find
vector
optim
indic
instead
choic
vector
type
depend
intend
specif
therapeut
use
retrovirus
rna
genom
copi
doublestrand
dna
turn
integr
host
genom
provir
dna
characterist
maintain
therapeut
use
retrovir
vector
perman
express
transgen
immun
respons
vector
weak
virus
modifi
longer
leav
cell
caus
damag
famili
retrovirida
divid
subgroup
oncoretrovirus
lentivirus
oncoretrovirus
transduc
prolifer
cell
primarili
use
ex
vivo
cellsfor
exampl
hematopoiet
stem
cellsar
remov
patient
transduc
retroviru
vector
tissuecultur
dish
later
readminist
patient
manner
children
treat
suffer
xscid
sever
combin
immunodefici
disord
caus
mutat
gc
interleukin
receptor
gene
locat
x
chromosom
presum
advantag
longterm
express
stabl
integr
host
genom
prove
disadvantag
howev
sinc
sever
children
develop
leukemia
consequ
treatment
retrovir
vector
integr
proxim
protooncogen
promot
led
anomal
transcript
express
find
show
safeti
vector
must
improv
time
howev
one
must
rememb
diseas
scid
frequent
untreat
mean
lead
earli
death
affect
children
lentivir
vector
exampl
deriv
human
immunodefici
viru
hiv
abil
transduc
quiescent
well
prolifer
cell
thu
increas
therapeut
rang
furthermor
oncogen
potenti
presum
less
g
glycoprotein
vesicular
stomat
viru
use
coat
protein
lentivir
vector
allow
transduct
almost
cell
type
demonstr
retorvir
vector
principl
suit
sirnamedi
gene
silenc
inhibit
report
gene
egfp
employ
medic
relev
purpos
specif
knockdown
oncogen
kra
allel
human
tumor
cell
caus
lose
tumorgen
addit
lentivir
vector
use
introduc
shrna
express
cassett
virus
receptor
host
cell
lentiviru
vector
prove
particularli
effici
inhibit
hepat
c
viru
hcv
vector
produc
sever
shrna
viru
genom
host
cell
receptor
immun
reaction
cytotox
cytotox
time
therebi
block
hcv
replic
express
cell
bind
hcv
surfac
protein
intens
effort
use
lentivir
vector
transfer
shrna
express
cassett
treatment
hiv
infect
ongo
clinic
trial
purpos
describ
section
adenovirus
linear
doublestrand
dna
genom
often
caus
respiratori
problem
human
genom
dna
adenovirus
remain
episom
infect
cell
risk
insert
mutagenesi
exist
unfortun
caus
power
immun
reaction
led
fatal
reaction
clinic
studi
part
earli
gene
remov
first
gener
adenovir
vector
earli
gene
andor
delet
second
gener
adenoviru
vector
reduc
immunogen
creat
addit
space
transgen
newest
vector
refer
gutless
code
sequenc
delet
besid
transgen
invert
termin
repeat
itr
packag
signal
remain
approach
drastic
reduc
toxic
immunogen
vector
enabl
longterm
express
transgen
adenovir
vector
alreadi
employ
differ
medic
area
knockdown
damag
gene
exampl
guinea
pig
pig
protect
infect
footandmouth
diseas
shrnaexpress
adenoviru
vector
adenoviru
vector
mediat
deliveri
shrna
express
cassett
also
develop
treatment
heart
diseas
disrupt
calcium
balanc
import
caus
heart
failur
rnaimedi
inhibit
phospholamban
inhibitor
sarcoplasm
reticulum
ca
pump
possibl
improv
calcium
uptak
sacroplasm
reticulum
primari
neonat
rat
cardiomyocyt
adenoassoci
virus
aav
belong
famili
parvovirida
possess
compar
small
linear
singlestrand
dna
genom
aav
attract
vector
gene
transfer
sinc
effici
transduc
target
cell
nonpathogen
human
natur
aav
integr
specif
region
chromosom
gene
requir
usual
delet
recombin
vector
remain
primarili
episom
despit
aav
vector
noteworthi
longterm
stabl
express
transgen
gene
therapeut
use
aav
serotyp
first
develop
vector
sinc
ineffici
transduc
mani
cell
type
muscl
cell
serotyp
use
past
year
expand
tropism
genom
vector
pack
capsid
serotyp
lead
creation
socal
pseudotyp
vector
cell
practic
given
tissu
transduc
disadvantag
convent
singlestrand
vectorsth
delay
start
express
transgenecould
also
elimin
maxim
gene
express
achiev
day
selfcomplementari
doublestrand
aav
vector
aav
vector
intens
employ
rnai
experi
numer
advantag
exampl
dopaminesynthes
enzym
tyrosin
hydroxylas
downregul
midbrain
neuron
mice
shrnaexpress
aav
vector
one
first
vivo
studi
result
behavior
chang
motorperform
deficit
alter
reaction
psychostimul
seen
faster
act
selfcomplementari
aav
vector
prove
use
cellcultur
experi
mrna
target
gene
reduc
transduct
cultur
ratlung
fibroblast
h
applic
rna
interfer
sequenc
human
genom
well
mani
eukaryot
model
organ
rate
one
import
develop
last
decad
life
scienc
mani
case
howev
sequenc
known
function
code
protein
remain
unknown
determin
gene
function
becom
one
import
task
present
research
time
complet
major
sequenc
project
rnai
establish
method
allow
creation
lossoffunct
phenotyp
compar
rapid
simpl
manner
led
adopt
year
rnai
standard
method
molecular
biolog
research
employ
larg
number
biochem
laboratori
sinc
silenc
base
pair
mrna
gene
interest
sirna
guid
strand
gene
function
investig
significantli
faster
smallmolecul
inhibitor
must
first
identifi
labori
highthroughput
screen
addit
close
relat
isoform
protein
select
turn
suitabl
select
target
sequenc
investig
specif
function
almost
never
possibl
pharmacolog
substanc
even
goal
pharmaceut
project
develop
tradit
drug
rnai
offer
rapid
method
valid
target
unspecif
effect
rnai
applic
discuss
section
must
howev
kept
mind
thu
control
alreadi
laid
specif
rnai
experi
proven
earli
stage
research
includ
among
thing
suitabl
control
knockdown
mrna
protein
level
doserespons
curv
sirna
well
use
multipl
sirna
target
besid
analysi
function
individu
gene
mani
gene
also
investig
time
use
angewandt
chemi
sirna
librari
first
exampl
everi
member
famili
deubiquitin
enzym
select
turn
shrna
approach
led
discoveri
knockdown
famili
cylindromatosi
tumor
suppressor
cyld
led
increas
activ
transcript
factor
nfkb
tnfa
stimul
figur
interestingli
activ
could
prevent
aspirin
deriv
result
patient
cylindromatosi
mostli
benign
tumor
skin
appendag
treat
salicyl
acid
case
led
full
remiss
exampl
illustr
rnai
led
new
indic
wellknown
drug
number
librari
sirna
endoribonucleaseprepar
sirna
shrnaexpress
retroviru
vector
develop
cover
entir
human
genom
genomewid
screen
primarili
use
virolog
oncolog
studi
way
cellular
factor
necessari
infect
could
identifi
comprehens
screen
sirna
approxim
human
gene
led
addit
inform
viral
life
cycl
also
identifi
new
potenti
therapeut
target
screen
retrovir
vector
mirnatyp
shrna
around
gene
protein
identifi
involv
prolifer
cancer
cell
genomewid
screen
potenti
tumor
suppressor
found
requir
block
prolifer
fibroblast
melanocyt
contain
activ
mutant
braf
protooncogen
therapeut
applic
decadeslong
experi
clinic
develop
antisens
oligonucleotid
ribozym
util
therapeut
applic
sirna
explain
first
rnai
treatment
start
human
three
half
year
sirna
first
use
mammalian
cell
antisens
oligonucleotid
sirna
differ
convent
substanc
size
largescal
synthesi
oligom
caus
consider
difficulti
high
cost
furthermor
two
strand
sirna
must
synthes
separ
subsequ
hybrid
process
guarante
format
uniform
drug
must
end
satisfi
requir
regulatori
author
local
applic
select
first
proofofconcept
studi
previous
discuss
deliveri
problem
tabl
show
advanc
rnaibas
clinic
trail
eye
spatial
welldefin
organ
low
nucleas
activ
activ
agent
inject
intravitr
directli
vitreou
bodi
compar
easili
two
oligonucleotid
approv
american
food
drug
administr
fda
treatment
eye
diseas
antisens
oligonucleotid
fomivirsen
direct
cytomegaloviru
caus
retin
aid
patient
macugen
aptam
treatment
agerel
macular
degener
amd
one
common
eye
diseas
among
elderli
first
rnaibas
clinic
studi
start
end
sirna
vegf
inhibit
express
vegf
block
neovascular
patient
amd
sirna
sinc
test
name
bevasiranib
phase
iii
trial
compani
opko
health
sirna
therapeut
sinc
bought
merck
co
inc
usa
initi
first
clinic
studi
chemic
modifi
sirna
sirna
code
stabil
unpair
deoxythymidin
phosphorothio
bond
invert
abas
sugar
residu
end
antisens
sens
strand
respect
direct
vegf
approach
also
enabl
treatment
patient
amd
intravitr
inject
sirna
reduc
area
neovascular
much
figur
function
tumor
suppressor
cyld
identifi
mean
rnai
screen
cyld
work
inhibitor
nfkb
signal
pathway
loss
cyld
function
lead
uncontrol
growth
pathway
also
inhibit
use
sodium
salicyl
traf
tnfreceptorassoci
factor
ikk
ikb
kinas
complex
scheme
adapt
ref
mous
model
choroid
neovascular
studi
kleinmann
et
al
alreadi
discuss
section
call
mechan
action
sirna
vegf
receptor
question
author
came
conclus
antiangiogen
effect
due
knockdown
target
gene
base
extracellular
activ
clinic
studi
sirna
hypoxiainduc
gene
use
treatment
amd
accord
quark
pharmaceut
approach
possibl
safer
effici
antivegf
substanc
viral
infect
present
increasingli
press
medic
problem
number
chronic
infect
associ
well
hbv
hcv
continu
increas
furthermor
new
variant
virus
influenza
viru
new
virus
sar
coronaviru
emerg
addit
threat
intens
global
travel
fact
human
anim
live
close
togeth
region
world
mean
new
danger
virus
must
expect
despit
enorm
need
antivir
agent
rel
approv
drug
treatment
viral
diseas
demonstr
necess
develop
new
antivir
strategi
rnai
base
complementari
base
pair
target
rna
guid
strand
sirna
result
allow
rapid
adapt
technolog
given
variant
viru
new
type
viru
great
advantag
rnai
rel
convent
approach
requir
timeconsum
optim
smallmolecul
substanc
sinc
first
report
antivir
effect
sirna
respiratori
syncyti
viru
rsv
success
rnai
applic
class
medic
relev
virus
includ
hbv
hcv
sarscoronaviru
influenza
viru
polio
viru
coxsacki
viru
publish
import
role
rnai
approach
virus
play
choic
suitabl
target
sequenc
viral
rna
often
contain
signific
secondari
structur
serious
imped
effici
inhibit
sirna
see
section
exampl
tar
rna
inaccess
risc
could
cleav
secondari
structur
broken
open
oligonucleotid
direct
region
neighbor
sirna
bind
site
one
biggest
problem
longterm
use
rnai
virus
viral
escap
polio
viru
hiv
case
describ
viral
replic
begin
block
effici
viru
titer
increas
select
mutant
overcom
inhibit
nonessenti
genesfor
exampl
nef
gene
delet
usual
howev
virus
overcom
rnaimedi
silenc
point
mutat
target
sequenc
comprehens
analysi
mutant
show
certain
posit
preferenti
mutat
avoid
viral
escap
sirna
direct
strongli
conserv
region
viru
nonstructur
protein
sever
affect
mutat
capsid
protein
howev
report
substitut
often
result
silent
mutat
affect
protein
function
escap
rout
viru
hinder
select
conserv
region
structur
function
destroy
mutat
way
coxsacki
viru
could
inhibit
long
period
sirna
conserv
cisact
replic
element
cre
sirna
target
structur
unimport
region
led
viral
escap
even
care
select
target
sequenc
howev
rnai
approach
requir
develop
combin
therapi
similar
alreadi
employ
convent
treatment
viral
infect
analog
highli
activ
antiretrovir
therapi
haart
sever
smallmolecul
activ
drug
use
sever
sirna
shrna
could
use
viru
combin
four
shrna
express
cassett
lentivir
vector
led
viral
escap
observ
singl
shrna
avoid
altern
use
sirna
viru
downregul
cellular
factor
viru
requir
enter
cell
replic
chanc
viral
escap
mutat
drastic
reduc
cellular
gene
critic
factor
howev
correspond
protein
essenti
cell
exampl
case
coreceptor
mutat
gene
consequ
health
individu
protect
person
infect
hematopoiet
stem
cell
protect
rnaimedi
knockdown
approach
howev
restrict
coxsacki
viru
adenoviru
receptor
led
signific
reduct
replic
recent
begun
clinic
trial
treatment
patient
combin
sever
target
rnabas
strategi
get
best
protect
escap
mutant
singl
lentivir
vector
express
shrna
gene
rev
tat
hammerhead
ribozym
decoy
oligonucleotid
transactiv
respons
tar
element
gene
transfer
occur
case
ex
vivo
haematopoet
stem
cell
remov
patient
transduc
tissu
cultur
vector
reinfus
therapeut
program
treatment
hbv
infect
compani
nucleon
inc
develop
vector
four
shrna
differ
segment
viral
genom
approach
prevent
viral
escap
phase
clinic
studi
vector
design
nuc
start
lung
one
organ
sirna
rel
easi
appli
rnai
approach
thu
promis
treatment
respiratori
diseas
infect
rsv
could
inhibit
intranas
applic
sirna
mous
model
result
clinic
studi
initi
test
well
sirna
toler
healthi
volunt
accord
recent
publish
chemi
result
seriou
side
effect
observ
system
bioavail
intranas
appli
sirna
minim
expect
subsequ
phase
ii
studi
investig
safeti
antivir
effect
infect
adult
sirna
accord
alnylam
pharmaceut
toler
well
show
statist
signific
antivir
activ
field
great
hope
place
rnai
cancer
research
requir
great
deal
imagin
expect
inhibit
factor
oncogen
could
block
uncontrol
prolifer
tumor
cell
express
gene
lead
angiogenesi
within
tumor
creat
new
blood
vessel
suppli
tumor
oxygen
nutrient
also
block
addit
target
may
chosen
respons
metastasi
sinc
case
primari
tumor
surgic
remov
metastas
repres
real
problem
final
rnai
employ
resensit
resist
tumor
cell
treatment
chemotherapeut
agent
radiotherapi
import
way
tumor
cell
becom
resist
chemotherapeut
agent
express
multidrug
resist
mdr
gene
mdr
express
suppress
sirna
cell
becom
vulner
chemotherapeut
mani
publish
studi
show
tumor
growth
could
slow
anim
model
rnai
exampl
sirna
inhibit
growth
tumor
variou
xenograft
mous
model
sirna
penetr
tumor
endotheli
cell
lipoplex
block
angiogenesi
interest
option
involv
increas
antitumor
activ
oncolyt
virus
rnai
viral
vector
usual
modifi
creation
longer
replic
see
section
oncolyt
adenovirus
replic
select
cancer
cell
destroy
cell
cell
lysi
viru
augment
shrna
express
cassett
exampl
mutat
kra
oncogen
inhibitori
effect
tumor
growth
increas
first
clinic
rnai
cancer
trial
patient
glioblastoma
multiform
treat
brain
tumor
almost
untreat
current
avail
mean
prognosi
affect
patient
poor
rnai
approach
direct
tenascinc
strongli
express
tumor
tissu
rnai
treatment
success
prevent
reemerg
oper
remov
glioblastoma
mani
patient
product
current
develop
senetek
plc
calando
pharma
employ
unmodifi
sirna
subunit
ribonucleotid
reductas
phase
studi
treatment
solid
tumor
wherebi
sirna
deliv
special
nanoparticl
compani
silenc
therapeut
plan
clinic
studi
sirna
lipoplex
liposom
formul
sirna
atuplex
direct
express
protein
kinas
compani
announc
clinic
trial
rnai
approach
variou
form
cancer
near
futur
clinic
studi
rnai
employ
therapeut
strategi
acut
kidney
failur
shown
temporari
inhibit
tumor
suppressor
prevent
cell
damag
exploit
sinc
sirna
inhibit
express
limit
period
time
safeti
test
phase
trial
patient
high
risk
kidney
failur
exist
major
cardiovascular
oper
januari
transderm
inc
began
clinic
studi
treatment
autosomaldomin
genet
diseas
pachyonychia
congenita
disrupt
keratin
sirna
intraderm
inject
specif
inhibit
express
keratin
mutat
respons
diseas
addit
blockad
endogen
mirna
test
therapeut
strategi
experi
nonhuman
primat
liverspecif
could
inhibit
complementari
lna
oligonucleotid
lna
system
intraven
administ
trigger
appar
toxic
side
effect
level
plasma
cholesterol
could
reduc
inhibit
mirna
interest
target
molecul
indic
sinc
also
requir
hcv
replic
accord
press
releas
danish
compani
santari
pharma
clinic
trial
lna
inhibitor
began
may
sinc
rnai
technolog
strongli
applicationori
great
commerci
signific
practic
applic
rnai
rest
sever
fundament
patent
import
includ
patent
known
tuschl
ii
well
kreutzerlimm
tuschl
ii
patent
refer
typic
base
pair
long
sirna
overhang
alreadi
grant
decis
regard
tuschl
patent
remain
open
kreutzerlimm
patent
grant
europ
yet
us
howev
precis
extent
yet
decid
strong
patent
posit
held
us
biotech
alnylam
pharmaceut
besid
name
core
patent
rnai
also
hold
patent
chemic
modif
deliveri
sirna
result
alnylam
made
sever
major
deal
exampl
extens
research
cooper
novarti
juli
roch
ag
receiv
alnylam
nonexclus
licenc
million
therapeut
use
sirna
alnylam
ip
european
research
unit
much
attent
gener
take
sirna
therapeut
merck
co
usa
billion
end
transact
show
major
pharmaceut
compani
recogn
potenti
rnai
prepar
invest
great
deal
new
technolog
detail
regard
patent
situat
well
relat
busi
rnai
field
brought
togeth
recent
review
summari
outlook
rna
interfer
develop
one
import
technolog
biomed
research
within
year
simpl
effici
possibl
inhibit
express
specif
gene
make
possibl
elucid
function
protein
far
unknown
howev
rnai
becom
standard
method
molecular
biologyit
alreadi
made
way
clinic
around
dozen
clinic
studi
base
rnai
alreadi
run
first
result
promis
basic
knockdown
technolog
use
diseas
deleteri
gene
overexpress
exampl
cancer
viral
infect
inflamm
two
major
obstacl
must
howev
overcom
becom
broadli
applic
standard
therapi
question
specif
effici
deliveri
target
cell
alreadi
explain
sirna
caus
unspecif
side
effect
activ
immun
system
undesir
effect
minim
clever
select
sequenc
use
modifi
nucleotid
immens
effort
undertaken
develop
carrier
system
sirna
deliv
target
cell
despit
advanc
last
year
develop
still
requir
get
system
appli
sirna
requir
site
action
viral
vector
system
shrna
express
cassett
offer
addit
option
effici
organspecif
deliveri
approach
must
howev
first
overcom
reserv
base
neg
experi
gene
therapi
two
strategiesth
deliveri
chemic
synthes
sirna
vectormedi
express
shrnascan
complement
either
approach
chosen
depend
requir
given
applic
anticip
advanc
next
year
solv
problem
vision
mani
rnai
research
could
becom
realiti
use
genomewid
screen
sirna
librari
allow
target
diseas
cancer
identifi
function
investig
valid
sirna
employ
screen
afterward
molecul
optim
chemic
modif
standard
manner
test
anim
model
special
deliveri
agent
sirna
correspond
shrna
employ
directli
test
human
approach
enabl
unpreced
acceler
develop
new
therapi
option
achiev
sirna
specif
inhibit
singl
target
gene
usual
attempt
howev
experi
antisens
field
shown
circumst
inadequ
complex
diseas
cancer
contrast
mirna
affect
mani
target
rna
comprehens
regul
achiev
inhibit
mirna
clinic
studi
inhibit
mirna
alreadi
begun
plan
near
futur
possibl
show
greater
therapeut
effect
come
year
show
whether
rnai
success
research
laboratori
also
live
promis
antisens
strategi
offer
new
medic
option
molecularbas
therapi
special
thank
go
cowork
whose
tireless
effort
contribut
advanc
research
group
would
like
thank
volker
erdmann
continu
support
habilit
thank
henri
fechner
kaufmann
harri
kurreck
hanspet
vornloch
denis
werk
critic
read
manuscript
erik
wade
translat
text
great
care
financi
support
research
effort
dfg
tp
bmbfrna
netzwerk
fond
der
chemisch
industri
grate
acknowledg
